DK1492789T3 - Tropanderivater som CCR5-modulatorer - Google Patents

Tropanderivater som CCR5-modulatorer

Info

Publication number
DK1492789T3
DK1492789T3 DK03710080T DK03710080T DK1492789T3 DK 1492789 T3 DK1492789 T3 DK 1492789T3 DK 03710080 T DK03710080 T DK 03710080T DK 03710080 T DK03710080 T DK 03710080T DK 1492789 T3 DK1492789 T3 DK 1492789T3
Authority
DK
Denmark
Prior art keywords
tropane derivatives
ccr5 modulators
ccr5
modulators
tropane
Prior art date
Application number
DK03710080T
Other languages
English (en)
Inventor
Patricia Ann Basford
Peter Thomas Stephenson
Stefan Colin John Taylor
Anthony Pfizer Global Rrc Wood
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0208071.1A external-priority patent/GB0208071D0/en
Priority claimed from GB0301575A external-priority patent/GB0301575D0/en
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK1492789T3 publication Critical patent/DK1492789T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
DK03710080T 2002-04-08 2003-03-31 Tropanderivater som CCR5-modulatorer DK1492789T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0208071.1A GB0208071D0 (en) 2002-04-08 2002-04-08 Tropane derivatives useful in therapy
GB0301575A GB0301575D0 (en) 2003-01-23 2003-01-23 Tropane derivatives useful in therapy

Publications (1)

Publication Number Publication Date
DK1492789T3 true DK1492789T3 (da) 2006-09-11

Family

ID=28793308

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03710080T DK1492789T3 (da) 2002-04-08 2003-03-31 Tropanderivater som CCR5-modulatorer

Country Status (40)

Country Link
EP (1) EP1492789B1 (da)
JP (2) JP3793200B2 (da)
KR (1) KR100734685B1 (da)
CN (1) CN1324025C (da)
AP (1) AP1789A (da)
AR (1) AR039383A1 (da)
AT (1) ATE328882T1 (da)
AU (1) AU2003214503B2 (da)
BR (1) BR0309118A (da)
CA (1) CA2481482C (da)
CR (1) CR7514A (da)
CU (1) CU23282A3 (da)
CY (1) CY1106114T1 (da)
DE (1) DE60305903T2 (da)
DK (1) DK1492789T3 (da)
DO (1) DOP2003000624A (da)
EA (1) EA007590B1 (da)
ES (1) ES2263960T3 (da)
GE (1) GEP20074210B (da)
HN (1) HN2003000114A (da)
HR (1) HRP20040940A2 (da)
IL (1) IL164261A0 (da)
IS (1) IS2577B (da)
MA (1) MA27190A1 (da)
MX (1) MXPA04009220A (da)
MY (1) MY134223A (da)
NI (1) NI200300053A (da)
NO (1) NO329674B1 (da)
NZ (1) NZ535452A (da)
OA (1) OA12798A (da)
PA (1) PA8570801A1 (da)
PE (1) PE20040082A1 (da)
PL (1) PL372968A1 (da)
PT (1) PT1492789E (da)
RS (1) RS51550B (da)
SI (1) SI1492789T1 (da)
TN (1) TNSN04194A1 (da)
TW (1) TWI280130B (da)
UY (1) UY27752A1 (da)
WO (1) WO2003084954A1 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
PL372968A1 (en) * 2002-04-08 2005-08-08 Pfizer Inc. Tropane derivatives as ccr5 modulators
WO2005023810A1 (en) 2003-09-10 2005-03-17 Virochem Pharma Inc. Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
KR100777885B1 (ko) * 2003-10-03 2007-11-28 ν™”μ΄μž μΈμ½”ν¬λ ˆμ΄ν‹°λ“œ Ｈｉｖ 및 염증 치료λ₯Ό μœ„ν•œ ｃｃｒ5 수용체 κΈΈν•­μ œ ν™œμ„±μ„κ°–λŠ” μ΄λ―Έλ‹€μ‘°ν”Όλ¦¬λ”˜ μΉ˜ν™˜λœ 트둜판 μœ λ„μ²΄
GB0323236D0 (en) * 2003-10-03 2003-11-05 Pfizer Ltd Chemical compounds
TW200533348A (en) 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
US8131026B2 (en) 2004-04-16 2012-03-06 Validity Sensors, Inc. Method and apparatus for fingerprint image reconstruction
WO2006041780A1 (en) 2004-10-04 2006-04-20 Validity Sensors, Inc. Fingerprint sensing assemblies comprising a substrate
WO2006064340A2 (en) * 2004-12-13 2006-06-22 Pfizer Limited Process for the preparation of n-acyl beta-aminoaldehydes
WO2008063600A2 (en) * 2006-11-17 2008-05-29 Concert Pharmaceuticals Inc. Triazolyl tropane derivatives
WO2008127060A1 (en) 2007-04-13 2008-10-23 Dong Wha Pharmaceutical Co. Ltd. Aspartate of 1-cyclopropyl-6-fluoro-7-(8-methoxyimino-2,6-diaza- spiro[3.4]oct-6-yl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid, method for preparing the same, and antimicrobial pharmaceutical composition comprising the same
ATE502939T1 (de) 2007-08-27 2011-04-15 Theravance Inc Disubstituierte alkyl-8-azabicycloΓ€3.2.1ΓΌoktan- verbindungen als mu-opioid-rezeptorantagonisten
CN101712679B (zh) * 2008-10-08 2013-04-10 δΈ­ε›½η§‘ε­¦ι™’δΈŠζ΅·θ―η‰©η ”η©Άζ‰€ δΈ€η§ι…°θƒΊη±»εŒ–εˆη‰©γ€ε…Άθ―η‰©η»„εˆη‰©εŠε…ΆεˆΆε€‡ζ–Ήζ³•ε’Œη”¨ι€”
CN102639504A (zh) * 2009-11-21 2012-08-15 εΌ—Β·ε“ˆε€«ζ›Ό-ζ‹‰η½—εˆ‡ζœ‰ι™ε…¬εΈ ζ‚ηŽ―ζŠ—η—…ζ―’εŒ–εˆη‰©
JP5731538B2 (ja) 2009-12-23 2015-06-10 をむをンウッド γƒ•γ‚‘γƒΌγƒžγ‚·γƒ₯ーティカルズ むンコーポレむテッド οΌ£ο½’ο½”ο½ˆοΌ’γƒ’γ‚Έγƒ₯レーター
MA34215B1 (fr) 2010-04-02 2013-05-02 Phivco 1 Llc Traitement d'association comprenant un antagoniste du rΓ©cepteur ccr5, un inhibiteur de la protΓ©ase du vih-1 et un accΓ©lΓ©rateur pharmacocinΓ©tique
US20130259830A1 (en) 2010-07-12 2013-10-03 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012009137A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizΓ‘lt szΓ‘rmazΓ©kai
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la SantΓ© et de la Recherche MΓ©dicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
CN106977511B (zh) * 2011-12-19 2019-04-12 δΈ­ε›½η§‘ε­¦ι™’δΈŠζ΅·θ―η‰©η ”η©Άζ‰€ δΈ€η§ζ°¨εŸΊδΈ™εŸΊε–δ»£ζ‰˜ηƒ·θƒΊη±»εŒ–εˆη‰©γ€ε…Άθ―η‰©η»„εˆη‰©εŠε…ΆεˆΆε€‡ζ–Ήζ³•ε’Œη”¨ι€”
JP6146990B2 (ja) * 2012-11-16 2017-06-14 γ‚³γƒ³γ‚΅γƒΌγƒˆ γƒ•γ‚‘γƒΌγƒžγ‚·γƒ₯ーティカルズ むンコーポレむテッド ι‡ζ°΄η΄ εŒ–γ•γ‚ŒγŸο½ƒο½†ο½”ο½’ε’—εΌ·η‰©θ³ͺ
GB201321748D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321749D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
HK1249893A1 (zh) 2015-03-31 2018-11-16 Vertex Pharmaceuticals (Europe) Limited 氘代vx-661
HK1258473A1 (zh) 2015-09-25 2019-11-15 Vertex Pharmaceuticals (Europe) Limited 氘代cftrε’žζ•ˆε‰‚
JP2017105824A (ja) * 2017-02-10 2017-06-15 γ‚³γƒ³γ‚΅γƒΌγƒˆ γƒ•γ‚‘γƒΌγƒžγ‚·γƒ₯ーティカルズ むンコーポレむテッド ι‡ζ°΄η΄ εŒ–γ•γ‚ŒγŸο½ƒο½†ο½”ο½’ε’—εΌ·η‰©θ³ͺ
CA3082444A1 (en) 2017-12-01 2019-06-06 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
US11649235B2 (en) 2018-03-19 2023-05-16 Emory University Pan-tropic entry inhibitors
JP6654223B2 (ja) * 2018-08-13 2020-02-26 バーテックス γƒ•γ‚‘γƒΌγƒžγ‚·γƒ₯ーティカルズ οΌˆγƒ¨γƒΌγƒ­γƒƒγƒ‘οΌ‰ γƒͺγƒŸγƒ†γƒƒγƒ‰ ι‡ζ°΄η΄ εŒ–γ•γ‚ŒγŸο½ƒο½†ο½”ο½’ε’—εΌ·η‰©θ³ͺ
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
WO2001080106A1 (en) * 2000-04-19 2001-10-25 Satoshi Yamazaki Advertising-tool distribution method and magnetic recorded medium for the software
CN100355753C (zh) * 2000-05-26 2007-12-19 θΎ‰η‘žε€§θ―εŽ‚ η”¨δΊŽεˆΆε€‡ε…·ζœ‰ζ²»η–—δ½œη”¨ηš„θŽ¨θͺηƒ·θ‘η”Ÿη‰©ηš„δΈ­ι—΄δ½“
PL372968A1 (en) * 2002-04-08 2005-08-08 Pfizer Inc. Tropane derivatives as ccr5 modulators

Also Published As

Publication number Publication date
CA2481482C (en) 2009-11-10
AP2004003147A0 (en) 2004-09-30
MXPA04009220A (es) 2005-09-30
JP2005532285A (ja) 2005-10-27
MY134223A (en) 2007-11-30
CY1106114T1 (el) 2011-06-08
WO2003084954A1 (en) 2003-10-16
PL372968A1 (en) 2005-08-08
HN2003000114A (es) 2004-05-05
BR0309118A (pt) 2005-02-01
AU2003214503A1 (en) 2003-10-20
EA200401167A1 (ru) 2005-04-28
NI200300053A (es) 2005-11-01
SI1492789T1 (sl) 2006-10-31
EA007590B1 (ru) 2006-12-29
NO329674B1 (no) 2010-11-29
DE60305903T2 (de) 2007-03-08
NZ535452A (en) 2006-11-30
CR7514A (es) 2004-11-08
ES2263960T3 (es) 2006-12-16
AU2003214503B2 (en) 2008-08-07
PA8570801A1 (es) 2004-11-26
OA12798A (en) 2006-07-10
CN1646526A (zh) 2005-07-27
KR100734685B1 (ko) 2007-07-02
NO20044615L (no) 2004-10-26
TW200403242A (en) 2004-03-01
IS7453A (is) 2004-09-16
HRP20040940A2 (en) 2005-04-30
RS51550B (sr) 2011-06-30
PE20040082A1 (es) 2004-03-20
DE60305903D1 (de) 2006-07-20
TNSN04194A1 (fr) 2007-03-12
JP4571078B2 (ja) 2010-10-27
ATE328882T1 (de) 2006-06-15
IS2577B (is) 2010-02-15
GEP20074210B (en) 2007-10-10
CN1324025C (zh) 2007-07-04
HK1076102A1 (en) 2006-01-06
CU23282A3 (es) 2008-06-30
EP1492789A1 (en) 2005-01-05
MA27190A1 (fr) 2005-01-03
IL164261A0 (en) 2005-12-18
CA2481482A1 (en) 2003-10-16
DOP2003000624A (es) 2003-10-15
UY27752A1 (es) 2003-11-28
EP1492789B1 (en) 2006-06-07
AR039383A1 (es) 2005-02-16
KR20040099420A (ko) 2004-11-26
TWI280130B (en) 2007-05-01
AP1789A (en) 2007-10-05
JP3793200B2 (ja) 2006-07-05
JP2006182784A (ja) 2006-07-13
RS88804A (sr) 2006-12-15
PT1492789E (pt) 2006-09-29

Similar Documents

Publication Publication Date Title
DK1492789T3 (da) Tropanderivater som CCR5-modulatorer
DK1284974T3 (da) Triazolyltropanderivater som CCR5-modulatorer
NO20052739D0 (no) CCR5-antagonister som medikamenter
NO20050426L (no) Arylkarbonylderivater som terapeutiske midler
NO20044654L (no) Piperidinoylpiperidiner som 5-HTIF-agonister
AU2003253535A1 (en) N-4-piperidinyl compounds as ccr5 modulators
DK1397364T3 (da) Hidtil ukendte pyrrolderivater som farmaceutiske midler
NO20055680D0 (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
NO20055135D0 (no) Fenylguinoliner og deres anvendelse som ostrogenreseptormodulatorer
NO20023283D0 (no) Flammestopper
ATE481402T1 (de) Pyrazolopyridin-derivate
NO20013149L (no) Piperidiner som CCR5-modulatorer
DK1501826T3 (da) Substituerede indoler som alpha-1-agonister
DK1789041T3 (da) Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
DK1797042T3 (da) Indozolonderivater som 11B-HSD1-inhibitorer
NO20050665L (no) Pyrrolidonderivater som MAOE inhibitoere
ATE456558T1 (de) Gabanerge modulatoren
NO20044092L (no) Oftalmisk sammensetning som innbefatter ascomycin
NO20043794L (no) Benzensulfonamidderivater som antipsykotiske midler
DE602004014772D1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
DK1648882T3 (da) 3-fluor-piperidiner som NMDA/NR2B-antagonister
NO20021251D0 (no) Tienoisoksazolyl- og tienylpyrrazolyl-fenoksysubstituerte propylderivater anvendelige som D4antagonister
DK1560828T3 (da) Imidazoquinolinderivater som adenosin-A3-receptorligander
IL177729A0 (en) N-piperidine derivatives as ccr3 modulators
ATE361911T1 (de) Piperidinderivate als ccr5-rezeptormodulatoren